<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18337">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934010</url>
  </required_header>
  <id_info>
    <org_study_id>AM-101-CL-12-03</org_study_id>
    <nct_id>NCT01934010</nct_id>
  </id_info>
  <brief_title>AM-101 in the Treatment of Post-Acute Tinnitus 1</brief_title>
  <acronym>AMPACT1</acronym>
  <official_title>AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auris Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Medical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and local tolerance of repeated
      treatment cycles of AM-101.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label extension study is assessing the safety and local tolerance of repeated
      treatment cycles of AM-101 in subjects previously treated in the scope of the TACTT2 study
      (NCT01803646).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hearing threshold</measure>
    <time_frame>Up to Day 203</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence of deterioration in hearing threshold in the treated ear(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hearing threshold</measure>
    <time_frame>Up to Day 252</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Difference and occurence of deterioration of hearing threshold in the treated ear(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>Throughout subject study participation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence and severity of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>AM-101 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM-101 gel for intratympanic injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM-101</intervention_name>
    <description>AM-101 gel for intratympanic injection</description>
    <arm_group_label>AM-101 injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of TACTT2 study;

          -  Negative pregnancy test (woman of childbearing potential);

          -  Willing and able to attend the study visits during at least one treatment cycle.

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Adverse event leading to treatment discontinuation in TACTT2;

          -  Meniere's Disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating
             hearing loss, otitis media, otitis externa, abnormality of tympanic membrane;

          -  Ongoing drug-based therapy for otitis media or otitis externa;

          -  Drug-based therapy known as potentially tinnitus-inducing;

          -  Other treatment of tinnitus;

          -  Drug abuse or alcoholism;

          -  Subjects with psychiatric diseases requiring drug treatment;

          -  Use of  antidepressant or anti-anxiety medication;

          -  Any clinically relevant disorder or abnormality in physical examination;

          -  Women who are breast-feeding, pregnant or who are planning to become pregnant during
             the study;

          -  Women of childbearing potential who are unwilling or unable to practice
             contraception.

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eaton</last_name>
    <phone>+1.513.579.9911</phone>
    <email>auris-trials@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medpace</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
